FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2729457268> ?p ?o ?g. }

• W2729457268 endingPage "2840" @default.
• W2729457268 startingPage "2820" @default.
• W2729457268 abstract "HomeCirculationVol. 117, No. 21ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive SummaryA Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Writing Committee Members Andrew E. Epstein, MD, FACC, FAHA, FHRS, Chair, John P. DiMarco, MD, PhD, FACC, FAHA, FHRS, Kenneth A. Ellenbogen, MD, FACC, FAHA, FHRS, N.A. Mark EstesIII, MD, FACC, FAHA, FHRS, Roger A. Freedman, MD, FACC, FHRS, Leonard S. Gettes, MD, FACC, FAHA, A. Marc Gillinov, MD, FACC, FAHA, Gabriel Gregoratos, MD, FACC, FAHA, Stephen C. Hammill, MD, FACC, FHRS, David L. Hayes, MD, FACC, FAHA, FHRS, Mark A. Hlatky, MD, FACC, FAHA, L. Kristin Newby, MD, FACC, FAHA, Richard L. Page, MD, FACC, FAHA, FHRS, Mark H. Schoenfeld, MD, FACC, FAHA, FHRS, Michael J. Silka, MD, FACC, Lynne Warner Stevenson, MD, FACC, FAHA and Michael O. Sweeney, MD, FACC Writing Committee Members Search for more papers by this author , Andrew E. EpsteinAndrew E. Epstein Search for more papers by this author , John P. DiMarcoJohn P. DiMarco Search for more papers by this author , Kenneth A. EllenbogenKenneth A. Ellenbogen Search for more papers by this author , N.A. Mark EstesIIIN.A. Mark EstesIII Search for more papers by this author , Roger A. FreedmanRoger A. Freedman Search for more papers by this author , Leonard S. GettesLeonard S. Gettes Search for more papers by this author , A. Marc GillinovA. Marc Gillinov Search for more papers by this author , Gabriel GregoratosGabriel Gregoratos Search for more papers by this author , Stephen C. HammillStephen C. Hammill Search for more papers by this author , David L. HayesDavid L. Hayes Search for more papers by this author , Mark A. HlatkyMark A. Hlatky Search for more papers by this author , L. Kristin NewbyL. Kristin Newby Search for more papers by this author , Richard L. PageRichard L. Page Search for more papers by this author , Mark H. SchoenfeldMark H. Schoenfeld Search for more papers by this author , Michael J. SilkaMichael J. Silka Search for more papers by this author , Lynne Warner StevensonLynne Warner Stevenson Search for more papers by this author and Michael O. SweeneyMichael O. Sweeney Search for more papers by this author Originally published15 May 2008https://doi.org/10.1161/CIRCUALTIONAHA.108.189741Circulation. 2008;117:2820–2840is corrected byCorrectionOther version(s) of this articleYou are viewing the most recent version of this article. Previous versions: May 15, 2008: Previous Version 1 Preamble…2821 1. Introduction…2822 1.1. Organization of Committee…2822 1.2. Document Review and Approval…2822 1.3. Methodology and Evidence…2822 2. Recommendations for Permanent Pacing in Sinus Node Dysfunction…2824 3. Recommendations for Acquired Atrioventricular Block in Adults…2825 4. Recommendations for Permanent Pacing in Chronic Bifascicular Block…2827 5. Recommendations for Permanent Pacing After the Acute Phase of Myocardial Infarction…2828 6. Recommendations for Permanent Pacing in Hypersensitive Carotid Sinus Syndrome and Neurocardiogenic Syncope…2828 7. Recommendations for Pacing After Cardiac Transplantation…2828 8. Recommendations for Permanent Pacemakers That Automatically Detect and Pace to Terminate Tachycardias…2828 9. Recommendations for Pacing to Prevent Tachycardia…2829 10. Recommendation for Pacing to Prevent Atrial Fibrillation…2829 11. Recommendations for Cardiac Resynchronization Therapy in Patients With Severe Systolic Heart Failure…2829 12. Recommendations for Pacing in Patients With Hypertrophic Cardiomyopathy…2829 13. Recommendations for Permanent Pacing in Children, Adolescents, and Patients With Congenital Heart Disease…2830 14. Recommendations for Implantable Cardioverter-Defibrillators…2830 15. Recommendations for Implantable Cardioverter-Defibrillators in Pediatric Patients and Patients With Congenital Heart Disease…2832References…2832Appendix 1. Author Relationships With Industry…2836Appendix 2. Peer Reviewer Relationships With Industry…2838Appendix 3. Abbreviations List…2840PreambleIt is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies as they are introduced and tested in the detection, management, or prevention of disease states. Rigorous and expert analysis of the available data documenting absolute and relative benefits and risks of those procedures and therapies can produce helpful guidelines that improve the effectiveness of care, optimize patient outcomes, and favorably affect the overall cost of care by focusing resources on the most effective strategies.The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly engaged in the production of such guidelines in the area of cardiovascular disease since 1980. The American College of Cardiology (ACC)/AHA Task Force on Practice Guidelines, whose charge is to develop, update, or revise practice guidelines for important cardiovascular diseases and procedures, directs this effort. Writing committees are charged with the task of performing an assessment of the evidence and acting as an independent group of authors to develop, update, or revise written recommendations for clinical practice.Experts in the subject under consideration have been selected from both organizations to examine subject-specific data and write guidelines. The process includes additional representatives from other medical practitioner and specialty groups when appropriate. Writing committees are specifically charged to perform a formal literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers and comorbidities and issues of patient preference that may influence the choice of particular tests or therapies are considered, as well as frequency of follow-up and cost-effectiveness. When available, information from studies on cost will be considered; however, review of data on efficacy and clinical outcomes will constitute the primary basis for preparing recommendations in these guidelines.The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual, potential, or perceived conflicts of interest that may arise as a result of an industry relationship or personal interest of the writing committee. Specifically, all members of the writing committee, as well as peer reviewers of the document, were asked to provide disclosure statements of all such relationships that may be perceived as real or potential conflicts of interest. Writing committee members are also strongly encouraged to declare a previous relationship with industry that may be perceived as relevant to guideline development. If a writing committee member develops a new relationship with industry during his or her tenure, he or she is required to notify guideline staff in writing. The continued participation of the writing committee member will be reviewed. These statements are reviewed by the parent task force, reported orally to all members of the writing committee at each meeting, and updated and reviewed by the writing committee as changes occur. Please refer to the methodology manual for ACC/AHA guideline writing committees for further description of the relationships with industry policy.1 See Appendix 1 for author relationships with industry and Appendix 2 for peer reviewer relationships with industry that are pertinent to this guideline.These practice guidelines are intended to assist health care providers in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management, and prevention of specific diseases or conditions. Clinical decision making should consider the quality and availability of expertise in the area where care is provided. These guidelines attempt to define practices that meet the needs of most patients in most circumstances. These guideline recommendations reflect a consensus of expert opinion after a thorough review of the available current scientific evidence and are intended to improve patient care.Patient adherence to prescribed and agreed upon medical regimens and lifestyles is an important aspect of treatment. Prescribed courses of treatment in accordance with these recommendations will only be effective if they are followed. Because lack of patient understanding and adherence may adversely affect treatment outcomes, physicians and other health care providers should make every effort to engage the patient in active participation with prescribed medical regimens and lifestyles.If these guidelines are used as the basis for regulatory or payer decisions, the ultimate goal is quality of care and serving the patient’s best interests. The ultimate judgment regarding care of a particular patient must be made by the health care provider and the patient in light of all of the circumstances presented by that patient. There are circumstances in which deviations from these guidelines are appropriate.The guidelines will be reviewed annually by the ACC/AHA Task Force on Practice Guidelines and will be considered current unless they are updated, revised, or sunsetted and withdrawn from distribution. The executive summary and recommendations are published in the May 27, 2008, issue of the Journal of the American College of Cardiology, May 27, 2008, issue of Circulation, and the June 2008 issue of Heart Rhythm. The full-text guidelines are e-published in the same issue of the journals noted above, as well as posted on the ACC (www.acc.org), AHA (http://my.americanheart.org), and Heart Rhythm Society (HRS) (www.hrsonline.org) Web sites. Copies of the full-text and the executive summary are available from each organization.Sidney C. Smith, Jr, MD, FACC, FAHA Chair, ACC/AHA Task Force on Practice Guidelines1. Introduction1.1. Organization of CommitteeThis revision of the “ACC/AHA/NASPE Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices” updates the previous versions published in 1984, 1991, 1998, and 2002. Revision of the statement was deemed necessary for multiple reasons: 1) Major studies have been reported that have advanced our knowledge of the natural history of bradyarrhythmias and tachyarrhythmias, which may be treated optimally with device therapy; 2) there have been tremendous changes in the management of heart failure that involve both drug and device therapy; and 3) major advances in the technology of devices to treat, delay, and even prevent morbidity and mortality from bradyarrhythmias, tachyarrhythmias, and heart failure have occurred.The committee to revise the “ACC/AHA/NASPE Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices” was composed of physicians who are experts in the areas of device therapy and follow-up and senior clinicians skilled in cardiovascular care, internal medicine, cardiovascular surgery, ethics, and socioeconomics. The committee included representatives of the American Association for Thoracic Surgery, Heart Failure Society of America, and Society of Thoracic Surgeons.1.2. Document Review and ApprovalThe document was reviewed by 2 official reviewers nominated by each of the ACC, AHA, and HRS and by 11 additional peer reviewers. Of the total 17 peer reviewers, 10 had no significant relevant relationships with industry. In addition, this document has been reviewed and approved by the governing bodies of the ACC, AHA, and HRS, which include 19 ACC Board of Trustees members (none of whom had any significant relevant relationships with industry), 15 AHA Science Advisory Coordinating Committee members (none of whom had any significant relevant relationships with industry), and 14 HRS Board of Trustees members (6 of whom had no significant relevant relationships with industry). All guideline recommendations underwent a formal, blinded writing committee vote. Writing committee members were required to recuse themselves if they had a significant relevant relationship with industry. The guideline recommendations were unanimously approved by all members of the writing committee who were eligible to vote.1.3. Methodology and EvidenceThe recommendations listed in this document are, whenever possible, evidence based. An extensive literature survey was conducted and limited to studies, reviews, and other evidence conducted in human subjects and published in English. Additionally, the committee reviewed documents related to the subject matter previously published by the ACC, AHA, and HRS. References selected and published in this document are representative and not all-inclusive.The committee reviewed and ranked evidence supporting current recommendations, with the weight of evidence ranked as Level A if the data were derived from multiple randomized clinical trials that involved a large number of individuals. The committee ranked available evidence as Level B when data were derived either from a limited number of trials that involved a comparatively small number of patients or from well-designed data analyses of nonrandomized studies or observational data registries. Evidence was ranked as Level C when the consensus of experts was the primary source of the recommendation. In the narrative portions of these guidelines, evidence is generally presented in chronological order of development. Studies are identified as observational, randomized, prospective, or retrospective. The committee emphasizes that for certain conditions for which no other therapy is available, the indications for device therapy are based on expert consensus and years of clinical experience and are thus well supported, even though the evidence was ranked as Level C. An analogous example is the use of penicillin in pneumococcal pneumonia, for which there are no randomized trials and only clinical experience. When indications at Level C are supported by historical clinical data, appropriate references (e.g., case reports and clinical reviews) are cited if available. When Level C indications are based strictly on committee consensus, no references are cited. In areas where sparse data were available (e.g., pacing in children and adolescents), a survey of current practices of major centers in North America was conducted to determine whether there was a consensus regarding specific pacing indications.The schema for classification of recommendations and level of evidence is summarized in Table 1, which also illustrates how the grading system provides an estimate of the size of the treatment effect and an estimate of the certainty of the treatment effect. Download figureDownload PowerPointTable 1. Applying Classification of Recommendations and Level of Evidence*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.The focus of these guidelines is the appropriate use of devices (e.g., pacemakers for bradyarrhythmias and heart failure management, cardiac resynchronization, and implantable cardioverter-defibrillators [ICDs]), not the treatment of cardiac arrhythmias. The fact that the use of a device for treatment of a particular condition is listed as a Class I indication (beneficial, useful, and effective) does not preclude the use of other therapeutic modalities that may be equally effective. As with all clinical practice guidelines, the recommendations in this document focus on treatment of an average patient with a specific disorder and may be modified by patient comorbidities, limitation of life expectancy because of coexisting diseases, and other situations that only the primary treating physician may evaluate appropriately.The term “symptomatic bradycardia” is used in this document. Symptomatic bradycardia is defined as a documented bradyarrhythmia that is directly responsible for development of the clinical manifestations of syncope or near syncope, transient dizziness or lightheadedness, or confusional states resulting from cerebral hypoperfusion attributable to slow heart rate. Fatigue, exercise intolerance, and congestive heart failure may also result from bradycardia. These symptoms may occur at rest or with exertion. Definite correlation of symptoms with a bradyarrhythmia is required to fulfill the criteria that define symptomatic bradycardia. Caution should be exercised not to confuse physiological sinus bradycardia (as occurs in highly trained athletes) with pathological bradyarrhythmias. Occasionally, symptoms may become apparent only in retrospect after antibradycardia pacing. Nevertheless, the universal application of pacing therapy to treat a specific heart rate cannot be recommended except in specific circumstances, as detailed subsequently.In these guidelines, the terms “persistent,” “transient,” and “not expected to resolve” are used but not specifically defined because the time element varies in different clinical conditions. The treating physician must use appropriate clinical judgment and available data in deciding when a condition is persistent or when it can be expected to be transient.Recommendations for ICD implantation have been updated to reflect the numerous new developments in this field and the voluminous literature related to the efficacy of these devices in the treatment and prophylaxis of sudden cardiac death (SCD) and malignant ventricular arrhythmias. Indications for ICDs, cardiac resynchronization therapy (CRT) devices, and combined ICDs and CRT devices are continuously changing and can be expected to change further as new trials are reported. Indeed, it is inevitable that the indications for device therapy will be refined with respect to both expanded use and the identification of patients expected to benefit the most from these therapies. Furthermore, it is emphasized that when a patient has an indication for both a pacemaker (whether it be single-chamber, dual-chamber, or biventricular) and an ICD, a combined device with appropriate programming is indicated.The 2008 revision reflects what the committee believes are the most relevant and significant advances in pacemaker/ICD therapy since the publication of these guidelines in the Journal of the American College of Cardiology and Circulation in 2002.2,3All recommendations assume that patients are treated with optimal medical therapy according to published guidelines, as had been required in all the randomized controlled clinical trials on which these guidelines are based. The committee believes that comorbidities, life expectancy, and quality-of-life issues must be addressed forthrightly with patients and their families. We have repeatedly used the phrase “reasonable expectation of survival with a good functional status for more than 1 year” to emphasize this integration of factors in decision making. Even when physicians believe that the anticipated benefits warrant device implantation, patients have the option to decline intervention after having been provided with a full explanation of the potential risks and benefits of device therapy. Finally, the committee is aware that other guidelines/expert groups have interpreted the same data differently.4–7In preparing this revision, the committee was guided by the following principles: Changes in recommendations and levels of evidence were made either because of new randomized trials or because of the accumulation of new clinical evidence and the development of clinical consensus.The committee was cognizant of the health care, logistic, and financial implications of recent trials and factored in these considerations to arrive at the classification of certain recommendations.For recommendations taken from other guidelines, wording changes were made to render some of the original recommendations more precise.The committee would like to re-emphasize that the recommendations in this guideline apply to most patients but may require modification because of existing situations that only the primary treating physician can evaluate properly.All of the listed recommendations for implantation of a device presume the absence of inciting causes that may be eliminated without detriment to the patient (e.g., nonessential drug therapy).The committee endeavored to maintain consistency of recommendations in this and other previously published guidelines. The recommendations on atrioventricular (AV) block associated with acute myocardial infarction closely follow those in the “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction.”8 However, because of the rapid evolution of pacemaker/ICD science, it has not always been possible to maintain consistency with other published guidelines.The following represents the complete set of recommendations for the implantation of antiarrhythmia devices. Prior executive summaries of ACC/AHA guidelines have included variable amounts of explanatory text ranging from none to large amounts. Because the supporting text in the full-text document was important to the present writing committee, we decided to provide only the recommendations in the Executive Summary and recommend readers access the full-text document for more explanation. Table 2 and Figures 1 and 2 are provided to help practitioners choose which pacing device is appropriate for an individual patient. Table 2. Choice of Pacemaker Generator in Selected Indications for PacingPacemaker GeneratorSinus Node DysfunctionAtrioventricular BlockNeurally Mediated Syncope or Carotid Sinus HypersensitivitySingle-chamber atrial pacemakerNo suspected abnormality of atrioventricular conduction and not at increased risk for future atrioventricular blockNot appropriateNot appropriateMaintenance of atrioventricular synchrony during pacing desiredSingle-chamber ventricular pacemakerMaintenance of atrioventricular synchrony during pacing not necessaryChronic atrial fibrillation or other atrial tachyarrhythmia or maintenance of atrioventricular synchrony during pacing not necessaryChronic atrial fibrillation or other atrial tachyarrhythmiaRate response available if desiredRate response available if desiredRate response available if desiredDual-chamber pacemakerAtrioventricular synchrony during pacing desiredAtrioventricular synchrony during pacing desiredSinus mechanism presentAtrial pacing desiredRate response available if desiredSuspected abnormality of atrioventricular conduction or increased risk for future atrioventricular blockRate response available if desiredRate response available if desiredSingle-lead, atrial-sensing ventricular pacemakerNot appropriateDesire to limit the number of pacemaker leadsNot appropriateDownload figureDownload PowerPointFigure 1. Selection of Pacemaker Systems for Patients With Sinus Node Dysfunction. Decisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker. AV indicates atrioventricular.Download figureDownload PowerPointFigure 2. Selection of Pacemaker Systems for Patients With Atrioventricular Block. Decisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker. AV indicates atrioventricular.2. Recommendations for Permanent Pacing in Sinus Node DysfunctionClass IPermanent pacemaker implantation is indicated for sinus node dysfunction (SND) with documented symptomatic bradycardia, including frequent sinus pauses that produce symptoms. (Level of Evidence: C)9–11Permanent pacemaker implantation is indicated for symptomatic chronotropic incompetence. (Level of Evidence: C)9–13Permanent pacemaker implantation is indicated for symptomatic sinus bradycardia that results from required drug therapy for medical conditions. (Level of Evidence: C)Class IIaPermanent pacemaker implantation is reasonable for SND with heart rate less than 40 bpm when a clear association between significant symptoms consistent with bradycardia and the actual presence of bradycardia has not been documented. (Level of Evidence: C)9–11,14–16Permanent pacemaker implantation is reasonable for syncope of unexplained origin when clinically significant abnormalities of sinus node function are discovered or provoked in electrophysiological studies. (Level of Evidence: C)17,18Class IIbPermanent pacemaker implantation may be considered in minimally symptomatic patients with chronic heart rate less than 40 bpm while awake. (Level of Evidence: C)9,11,12,14–16Class IIIPermanent pacemaker implantation is not indicated for SND in asymptomatic patients. (Level of Evidence: C)Permanent pacemaker implantation is not indicated for SND in patients for whom the symptoms suggestive of bradycardia have been clearly documented to occur in the absence of bradycardia. (Level of Evidence: C)Permanent pacemaker implantation is not indicated for SND with symptomatic bradycardia due to nonessential drug therapy. (Level of Evidence: C)3. Recommendations for Acquired Atrioventricular Block in AdultsClass IPermanent pacemaker implantation is indicated for third-degree and advanced second-degree AV block at any anatomic level associated with bradycardia with symptoms (including heart failure) or ventricular arrhythmias presumed to be due to AV block. (Level of Evidence: C)15,19–21Permanent pacemaker implantation is indicated for third-degree and advanced second-degree AV block at any anatomic level associated with arrhythmias and other medical conditions that require drug therapy that results in symptomatic bradycardia. (Level of Evidence: C)15,19–21Permanent pacemaker implantation is indicated for third-degree and advanced second-degree AV block at any anatomic level in awake, symptom-free patients in sinus rhythm, with documented periods of asystole greater than or equal to 3.0 seconds22) or any escape rate less than 40 bpm, or with an escape rhythm that is below the AV node. (Level of Evidence: C)9,14Permanent pacemaker implantation is indicated for third-degree and advanced second-degree AV block at any anatomic level in awake, symptom-free patients with atrial fibrillation and bradycardia with 1 or more pauses of at least 5 seconds or longer. (Level of Evidence: C)Permanent pacemaker implantation is indicated for third-degree and advanced second-degree AV block at any anatomic level after catheter ablation of the AV junction. (Level of Evidence: C)23,24Permanent pacemaker implantation is indicated for third-degree and advanced second-degree AV block at any anatomic level associated with postoperative AV block that is not expected to resolve after cardiac surgery. (Level of Evidence: C)21,25–27Permanent pacemaker implantation is indicated for third-degree and advanced second-degree AV block at any anatomic level associated with neuromuscular diseases with AV block, such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular atrophy, with or without symptoms. (Level of Evidence: B)28–34Permanent pacemaker implantation is indicated for second-degree AV block with associated symptomatic bradycardia regardless of type or site of block. (Level of Evidence: B)35Permanent pacemaker implantation is indicated for asymptomatic persistent third-degree AV block at any anatomic site with average awake ventricular rates of 40 bpm or faster if cardiomegaly or left ventricular (LV) dysfunction is present or if the site of block is below the AV node. (Level of Evidence: B)20,36Permanent pacemaker implantation is indicated for second- or third-degree AV block during exercise in the absence of myocardial ischemia. (Level of Evidence: C)37,38Class IIaPermanent pacemaker implantation is reasonable for persistent third-degree AV block with an escape rate greater than 40 bpm in asymptomatic adult patients without cardiomegaly. (Level of Evidence: C)15,19–21,38,39Permanent pacemaker implantation is reasonable for asymptomatic second-degree AV block at intra- or infra-His levels found at electrophysiological study. (Level of Evidence: B)20,35,36Permanent pacemaker implantation is reasonable for first- or second-degree AV block with symptoms similar to those of pacemaker syndrome or hemodynamic compromise. (Level of Evidence: B)40,41Permanent pacemaker i" @default.
• W2729457268 created "2017-07-14" @default.
• W2729457268 creator A5008701724 @default.
• W2729457268 creator A5010870828 @default.
• W2729457268 creator A5013165945 @default.
• W2729457268 creator A5017629157 @default.
• W2729457268 creator A5024045722 @default.
• W2729457268 creator A5026298001 @default.
• W2729457268 creator A5028043367 @default.
• W2729457268 creator A5031070551 @default.
• W2729457268 creator A5034586607 @default.
• W2729457268 creator A5038289246 @default.
• W2729457268 creator A5041446600 @default.
• W2729457268 creator A5041923394 @default.
• W2729457268 creator A5046638139 @default.
• W2729457268 creator A5048979901 @default.
• W2729457268 creator A5054626427 @default.
• W2729457268 creator A5056183044 @default.
• W2729457268 creator A5059069393 @default.
• W2729457268 creator A5060157223 @default.
• W2729457268 creator A5065738410 @default.
• W2729457268 creator A5065932248 @default.
• W2729457268 creator A5066843009 @default.
• W2729457268 creator A5067427901 @default.
• W2729457268 creator A5069545551 @default.
• W2729457268 creator A5070148218 @default.
• W2729457268 creator A5071011669 @default.
• W2729457268 creator A5073293058 @default.
• W2729457268 creator A5077817917 @default.
• W2729457268 creator A5078601261 @default.
• W2729457268 creator A5080291972 @default.
• W2729457268 creator A5081882998 @default.
• W2729457268 creator A5084054817 @default.
• W2729457268 creator A5084244205 @default.
• W2729457268 creator A5086040903 @default.
• W2729457268 creator A5086111395 @default.
• W2729457268 creator A5087040824 @default.
• W2729457268 creator A5088028306 @default.
• W2729457268 date "2008-05-27" @default.
• W2729457268 modified "2023-10-12" @default.
• W2729457268 title "ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary" @default.
• W2729457268 cites W117978725 @default.
• W2729457268 cites W1246307158 @default.
• W2729457268 cites W1538342238 @default.
• W2729457268 cites W1580175484 @default.
• W2729457268 cites W159126720 @default.
• W2729457268 cites W1601929881 @default.
• W2729457268 cites W1925145848 @default.
• W2729457268 cites W1965111694 @default.
• W2729457268 cites W1967528467 @default.
• W2729457268 cites W1974022021 @default.
• W2729457268 cites W1974369276 @default.
• W2729457268 cites W1978806685 @default.
• W2729457268 cites W1982333867 @default.
• W2729457268 cites W1987568857 @default.
• W2729457268 cites W1988562442 @default.
• W2729457268 cites W1991706424 @default.
• W2729457268 cites W1993851832 @default.
• W2729457268 cites W1995145907 @default.
• W2729457268 cites W1996637832 @default.
• W2729457268 cites W1997494786 @default.
• W2729457268 cites W2001836991 @default.
• W2729457268 cites W2006297977 @default.
• W2729457268 cites W2008800954 @default.
• W2729457268 cites W2010065371 @default.
• W2729457268 cites W2011348722 @default.
• W2729457268 cites W2012300598 @default.
• W2729457268 cites W2012574332 @default.
• W2729457268 cites W2014006919 @default.
• W2729457268 cites W2016999820 @default.
• W2729457268 cites W2018482790 @default.
• W2729457268 cites W2019566486 @default.
• W2729457268 cites W2027106142 @default.
• W2729457268 cites W2028397773 @default.
• W2729457268 cites W2028569948 @default.
• W2729457268 cites W2028890282 @default.
• W2729457268 cites W2029116764 @default.
• W2729457268 cites W2029244128 @default.
• W2729457268 cites W2029850405 @default.
• W2729457268 cites W2032350844 @default.
• W2729457268 cites W2035581854 @default.
• W2729457268 cites W2035667813 @default.
• W2729457268 cites W2036386465 @default.
• W2729457268 cites W2038668950 @default.
• W2729457268 cites W2038768903 @default.
• W2729457268 cites W2038802441 @default.
• W2729457268 cites W2039262324 @default.
• W2729457268 cites W2040567211 @default.
• W2729457268 cites W2040586624 @default.
• W2729457268 cites W2041239527 @default.
• W2729457268 cites W2042908317 @default.
• W2729457268 cites W2049835751 @default.
• W2729457268 cites W2052796101 @default.
• W2729457268 cites W2054878936 @default.
• W2729457268 cites W2056184456 @default.
• W2729457268 cites W2059208803 @default.
• W2729457268 cites W2060082762 @default.
• W2729457268 cites W2061789761 @default.

• next